MedTrace Logo

Investigating the Long-term Cardiac Sequelae of Trastuzumab Therapy

NCT05019365 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2021-08-24

No results posted yet for this study

Summary

The introduction of trastuzumab for the treatment of patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer has had a major impact upon cancer outcomes. However, cardiac toxicity remains a substantial concern. Conventionally, this toxicity has been considered as a transient and reversible phenomenon occurring in the immediate peri-treatment period in around 20% of patients. Current guidelines recommend monitoring heart function during treatment and at completion. Recent registry data suggest that trastuzumab-related cardiotoxicity may also manifest in the longer-term. The nature and longer-term prevalence of left ventricular dysfunction with HER2 positive breast cancer treated with trastuzumab is unclear. The aim of this project is to define the prevalence of left ventricular dysfunction late after completion of trastuzumab therapy.

Conditions

Sponsors & Collaborators

  • NHS Greater Glasgow and Clyde

    collaborator OTHER

  • Tenovus Scotland

    collaborator OTHER

  • University of Glasgow

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-15
Primary Completion
2022-05-25
Completion
2022-11-25

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05019365 on ClinicalTrials.gov